Lorecivivint for Osteoarthritis

"According to the inclusionary age parameters set for this particular trial, eligible participants must be between 41 and 81 years old."

"Lorecivivint is only being studied in one active trial across 47 cities and 1 country. The first study for Lorecivivint was run in 2020 by Biosplice Therapeutics, Inc. That initial Phase 3 drug approval stage involved 276 participants and completed successfully. Since then, a total of 18290 trials have been conducted."

"This research is no longer enrolling patients. The trial was announced on 8/25/2020 and the last update was on 4/14/2022. For those still searching, there are 724 ongoing trials for osteoarthritis, knee and 1 study for Lorecivivint that are presently recruiting individuals."

"The requirements for patients that wish to enroll in this study are as follows: a diagnosis of osteoarthritis, knee pain, and an age between 41 and 81. This clinical trial has space for 276 individuals in total."

"Currently, this study is enrolling patients at 27 clinical sites. The locations of these facilities are listed on the website and include major cities such as New Orleans, Winston-Salem and Winter Haven. Additionally, there are 27 other locations spread out across different cities. If you choose to enroll in this study, try to select a clinic that is nearest to your location to minimize travel requirements."

"According to the sponsor of this trial, Biosplice Therapeutics, Inc., the primary outcome will be safety-related. This will be measured by observing any adverse effects or serious adverse events that occur over the course of the study in relation to a parent-study baseline. Additionally, secondary outcomes being assessed include changes in physical function as determined by subscores on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Another metric for change that will be monitored is joint space width as observed via X-ray radiograph."

"There is some evidence for efficacy and multiple data sets indicating safety, so our team has given Lorecivint a score of 3."

"At present, there is 1 ongoing clinical trial evaluating the efficacy of Lorecivivint. This particular study is in Phase 3. In addition, 47 medical facilities across the globe are currently running trials for this medication with many of them being based in Las Vegas, Nevada."

"The specified trial is no longer recruiting patients. According to the information available, it was first posted on 8/25/2020 and last edited on 4/14/2022. There are presently 724 clinical trials actively looking for participants with osteoarthritis and 1 study for Lorecivivint that needs participants."